834 related articles for article (PubMed ID: 11179262)
21. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.
Keller TT; Squizzato A; Middeldorp S
Cochrane Database Syst Rev; 2007 Jul; (3):CD005158. PubMed ID: 17636787
[TBL] [Abstract][Full Text] [Related]
22. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
Gelbenegger G; Postula M; Pecen L; Halvorsen S; Lesiak M; Schoergenhofer C; Jilma B; Hengstenberg C; Siller-Matula JM
BMC Med; 2019 Nov; 17(1):198. PubMed ID: 31679516
[TBL] [Abstract][Full Text] [Related]
23. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.
Squizzato A; Keller T; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2011 Jan; (1):CD005158. PubMed ID: 21249668
[TBL] [Abstract][Full Text] [Related]
24. A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies.
Shah R; Khan B; Latham SB; Khan SA; Rao SV
Am J Med; 2019 Nov; 132(11):1295-1304.e3. PubMed ID: 31153866
[TBL] [Abstract][Full Text] [Related]
25. Aspirin for primary prevention of cardiovascular disease events.
Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR
Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080
[TBL] [Abstract][Full Text] [Related]
26. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
27. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
[TBL] [Abstract][Full Text] [Related]
28. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
[TBL] [Abstract][Full Text] [Related]
29. Aspirin for primary prevention: yes or no?
Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
[TBL] [Abstract][Full Text] [Related]
30. The aspirin controversy in primary prevention.
Raju NC; Eikelboom JW
Curr Opin Cardiol; 2012 Sep; 27(5):499-507. PubMed ID: 22874127
[TBL] [Abstract][Full Text] [Related]
31. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
[TBL] [Abstract][Full Text] [Related]
32. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
[TBL] [Abstract][Full Text] [Related]
33. Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.
Prescrire Int; 2010 Nov; 19(110):258-61. PubMed ID: 21284360
[TBL] [Abstract][Full Text] [Related]
34. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.
Li L; Geraghty OC; Mehta Z; Rothwell PM;
Lancet; 2017 Jul; 390(10093):490-499. PubMed ID: 28622955
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of aspirin treatment strategies for primary prevention of cardiovascular diseases: A decision-analytic Markov modelling study].
Zhang ML; Liu QP; Gong C; Wang JM; Zhou TJ; Liu XF; Shen P; Lin HB; Tang X; Gao P
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):480-487. PubMed ID: 37291924
[TBL] [Abstract][Full Text] [Related]
36. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.
Meade TW; Brennan PJ
BMJ; 2000 Jul; 321(7252):13-7. PubMed ID: 10875825
[TBL] [Abstract][Full Text] [Related]
37. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.
Rothberg MB; Celestin C; Fiore LD; Lawler E; Cook JR
Ann Intern Med; 2005 Aug; 143(4):241-50. PubMed ID: 16103468
[TBL] [Abstract][Full Text] [Related]
38. A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Wu IC; Hsieh HM; Yu FJ; Wu MC; Wu TS; Wu MT
Eur J Clin Invest; 2016 Feb; 46(2):130-40. PubMed ID: 26640116
[TBL] [Abstract][Full Text] [Related]
39. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Timmis A; Rapsomaniki E; Chung SC; Pujades-Rodriguez M; Moayyeri A; Stogiannis D; Shah AD; Pasea L; Denaxas S; Emmas C; Hemingway H
BMJ; 2016 Jun; 353():i3163. PubMed ID: 27334486
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
